Latest Breaking News On - Beijing cancer - Page 4 : comparemela.com
ECR Minerals PLC jumps after buying a second drilling rig for Australian project
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
GYG PLC sees its shares sink by 14% after it takes out emergency loan
proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Transcenta Provides Program Update for Anti-Claudin18 2 Monoclonal Antibody TST001 and Reports Promising Early Anti-Tumor Responses in Patients with Gastric Cancer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
SUZHOU, China, June 1, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced completion of first patient dosing in PET-CT imaging study of radionuclide-labeled CLDN18.2 antibody.
The study was led by Professor Lin Shen and Dr. Hua Zhu, from Beijing Cancer Hospital, the objective of the study is to construct a non-invasive approach of
124I-18B10 PET-CT to detect the CLDN18.2 expression of tumor lesions in patients with gastrointestinal and other solid tumors, and to identify patients benefited from CLDN18.2 targeting treatment. The current preclinical findings showed that the antibody probe has high specificity to CLDN18.2 and it was specifically enriched in CLDN18.2 positive tumor site in tumor-bearing mice rather than normal tissues. The results of this study were presented in the
Share this article
Share this article
SUZHOU, China, May 19, 2021 /PRNewswire/ Transcenta Holding Limited ( Transcenta ), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been presented as an abstract online publication at the 2021 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract #e14547, 5:00 PM, U.S. East Time, Wednesday, May 19, 2021).
The study, presented at the 2021 ASCO annual meeting by abstract, was led by Professor Lin Shen from Beijing Cancer Hospital, and was a Phase I study of MSB2311 with a unique pH-dependent antigen binding property in Chinese patients with advanced solid tumors and lymphoma. Its primary objectives were to e